Weight Loss Drugs Spark NHS Access Debate and Beer Sales Warning
💡 Why it matters
As weight-loss drugs become more widespread, they could simultaneously strain healthcare budgets and disrupt industries that rely on alcohol sales, prompting a need for cross-sector adaptation.
MPs have criticized NHS plans to offer Mounjaro to only 6% of eligible patients by 2028 as unambitious, while Heineken warns that the popularity of GLP-1 drugs like Wegovy could reduce beer consumption in British pubs.
Want more context?
Help us choose what to research next.
📡 Where we spotted it (2)
BBC News
Give more people weight-loss jabs on the NHS, say MPs
19h ago
›
The Guardian
Boom in weight-loss drugs could lead to drop in beer sales, Heineken warns British pubs
10h ago
›